SAN DIEGO, Dec. 7, 2022 /PRNewswire/ — Pimera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing breakthrough medicines for cancer and other diseases with high unmet medical need, announced today that Pimera’s President and CEO, Mustapha Haddach, Ph.D., will present a corporate overview at the Biotech Showcase 2023 meeting on Monday, January 9, 2023, at 5:15 PM. The Biotech Showcase Conference is taking place in San Francisco in parallel to the J.P. Morgan (JPM) 41^st Annual HealthCare Conference.

The Company will be available to meet potential partners, collaborators, and investors. One-to-one appointments may be requested as follows:

• The Biotech Showcase partnering platform: https://informaconnect.com/biotech-showcase/
• Biotechnology Innovation Organization (BIO) partnering platform: https://www.bio.org/events/bio-partnering-jpm

Pimera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on developing breakthrough therapeutics for cancer and other major unmet medical needs. Pimera’s lead program, PMR-116, is designed to target dysregulated RNA polymerase I (Pol I) transcription in MYC-driven cancers. Pol I transcription of ribosomal RNA genes is tightly regulated downstream of oncogenic pathways, and its dysregulation is a common feature in cancer and other human diseases. Pimera is advancing PMR-116 through dose escalation in a Phase 1a/1b clinical trial being conducted in Australia.

For more information on Pimera, please visit www.pimeratx.com and engage with us on LinkedIn.

Media and Investor Contact:
Amy Conrad
Juniper Point
(858) 366-3243
amy@juniper-point.com

SOURCE Pimera Therapeutics